SCHEMBL19952874

SCHEMBL19952874

CCC(COC)Oc1nc(C)nc(Nc2ccc(OC)cc2C)c1C

nearest known ligand 0.48

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 14/20 0.48
GAA P10253 1/20 0.39
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
PIK3CA P42336 1/20 0.35
PRKDC P78527 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30514691 1.00 CRHR1 (0.48) CRHR1GAAADRA2AADRA2CADRA1D
SCHEMBL21447121 0.87 CRHR1 (0.36) CRHR1
SCHEMBL21447140 0.87 MKNK2 (0.37) CRHR1
SCHEMBL21447286 0.86 CRHR1 (0.38) CRHR1
SCHEMBL21447294 0.81 CRHR1 (0.38) CRHR1GAA
SCHEMBL21447450 0.81 CRHR1 (0.57) CRHR1GAAADRA2AADRA2CADRA1D
SCHEMBL21447164 0.79 CRHR1 (0.45) CRHR1
SCHEMBL21447293 0.79 CRHR1 (0.37) CRHR1
SCHEMBL21447122 0.78 MKNK2 (0.35) CRHR1
SCHEMBL21447176 0.77 CRHR1 (0.37) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3510029-B1 ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION UNIV CALIFORNIA (US) 2025-11-05 EP disclosed
CN-109906222-B Allosteric corticotropin releasing factor receptor 1 (CRFR 1) antagonists that reduce P-TAU and improve cognition 加利福尼亚大学董事会 2023-08-01 CN disclosed
US-11077108-B2 Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-03 US disclosed
US-11077108-B2 Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-08-03 US disclosed
US-20190307747-A1 ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-10-10 US disclosed
US-20190307747-A1 ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-10-10 US disclosed
EP-3510029-A1 ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION The Regents of The University of California (US) 2019-07-17 EP disclosed
WO-2018048953-A1 ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11077108-B2 Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-tau and improve cognition CRHR1, CRH, CRHR2 CRHR1 1/4885GAA 3187/4885ADRA2A 114/4885
US-20190307747-A1 ALLOSTERIC CORTICOTROPIN-RELEASING FACTOR RECEPTOR 1 (CRFR1) ANTAGONISTS THAT DECREASE P-TAU AND IMPROVE COGNITION CRHR1, CRH, CRHR2 CRHR1 1/4885GAA 3780/4885ADRA2A 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.